|
|
|
|
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
Dublin - Research and Markets (http://www.researchandmarkets.com/research/7fd315/drug-delivery-in-c) has announced the addition of Jain PharmaBiotech's new report ' ' to their offering.The delivery of drugs to central nervous system (CNS) is a...
|
|
|
AMT To Present at the BIO CEO & Investors Conference ' 9th February 2010
CNS Diseases Breaking News News source: Business Wire AMT is a leader in the field of gene therapy.Its first product is in registration in EU for Lipoprotein Lipase Deficiency, an orphan condition. AMT's other development programmes include:...
|
|
|
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.(ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system...
|
|
|
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
PALO ALTO, CA, Feb 8 --(HSMN NewsFeed)-- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing products that address critical unmet needs primarily in the treatment of neurodegenerative diseases,...
|
|
|
Lupin Receives FDA Approval For Amlodipine/Benazepril Capsules
Baltimore,MD /PRNewswire/ -- Lupin Pharmaceuticals, Inc.announced recently that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial...
|
|
|
Addex: ADX71943 Demonstrates Analgesic Effects In Pain Models
Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced...
|
|
|
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.(ALKS - Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders,...
|
|
|
Lupin Receives FDA Approval for Amlodipine/Benazepril Capsules
BALTIMORE, Feb.8 /PRNewswire/ Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial...
|
|
|
Neurologic Disease Despite Undetectable Viral Load & The Use of Drugs That Penetrate Well the CSF - pdf of full article attached
"The highest drug levels in the CSF were found for indinavir, nevirapine, abacavir, maraviroc, and lamivudine" "In conclusion, physicians should be aware of the possibility of acute HIV-associated CNS disorders even in the presence of minor neurological...
|
|
|
Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic in Acute Post-Operative Pain
SHELTON, Conn.Significant pain relief was observed in CR845-treated patients over placebo from 4-8 hrs post-drug administration, as exemplified by a significant change in pain intensity difference ( ) scores (p<0.05). In addition, CR845-treated subjects...
|
|
|
Trevena Names David Soergel, M.D. Vice President and Head, Clinical Development
Trevena Continues to Add Proven Industry Expertise to Corporate Leadership Team KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Feb 8, 2010 - Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that it has named...
|
|
|
Alkermes Retains Neutral Rec - Analyst Blog
We maintain our Neutral rating on Alkermes, Inc.( ALKS ) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous...
|
|
|
Lupin Receives FDA Approval for Amlodipine/Benazepril Capsules
BALTIMORE, Feb.8 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules.
|
|
|
Trevena Names David Soergel, M.D. Vice President and Head, Clinical Development
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that it has named David Soergel, M.D.vice president and head, clinical development. In this role, Dr. Soergel is responsible for shaping Trevenas...
|
|
|
Lupin Receives FDA Approval for Amlodipine/Benazepril Capsules
Companies mentioned in this article: Lupin Pharmaceuticals, Inc.BALTIMORE, Feb. 8 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine...
|
|
|
Cohn & Wolfe Adds Industry Veteran, MaryEllen O'Donohue, as Senior Strategist and Client Counselor
NEW YORK, Feb.8 /PRNewswire/ -- Cohn & Wolfe, a leading global communications agency, announced today that industry veteran MaryEllen O'Donohue has joined the firm as Executive Vice President, Strategy and Client Service. In the role, O'Donohue will...
|
|
|
Cohn & Wolfe Adds Industry Veteran, MaryEllen O'Donohue, as Senior Strategist and Client Counselor
NEW YORK, Feb.8 /PRNewswire/ -- Cohn & Wolfe, a leading global communications agency, announced today that industry veteran MaryEllen O'Donohue has joined the firm as Executive Vice President, Strategy and Client Service. In the role, O'Donohue will...
|
|
|
Addex Pharmaceuticals (CH) - Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
- Addex Pharmaceuticals (SIX:ADXN), the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain.In the first model, ADX71943 reversed complete Freund...
|
|
|
Trevena Names David Soergel, M.D. Vice President and Head, Clinical Development
Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that it has named David Soergel, M.D.vice president and head, clinical development. In this role, Dr. Soergel is responsible for shaping Trevenas...
|
|
|
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing products that address critical unmet needs primarily in the treatment of neurodegenerative diseases, announced today that Andrew Gengos has been...
|
|
|
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
'Andrew's considerable biopharmaceutical industry experience in finance, strategy and business development will be a tremendous asset for Neuraltus and will enable the company to achieve its ambitious goals,' said Ari Azhir, PhD, a Neuraltus founder and Chief...
|
|
|
Trevena Names David Soergel, M.D. Vice President and Head, Clinical Development
Companies mentioned in this article: Trevena Inc.KING OF PRUSSIA, Pa. -- (BUSINESS WIRE) -- Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that it has named David Soergel, M.D. vice president...
|
|
|
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
PALO ALTO, CA -- (Marketwire) -- 02/08/10 -- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing products that address critical unmet needs primarily in the treatment of neurodegenerative diseases,...
|
|
|
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO
PALO ALTO, CA--(Marketwire - 02/08/10) - Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing products that address critical unmet needs primarily in the treatment of neurodegenerative diseases,...
|
|
|
Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models
Addex Pharmaceuticals / processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced today that ADX71943 has demonstrated...
|
